Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: November 2023 (Report Date: November 14, 2023)
Context: This filing incorporates by reference a press release dated November 14, 2023 (Exhibit 99.1). The document serves as a formal notification to the SEC regarding a material event but does not contain the full text of the press release or detailed financial statements within the provided excerpt.
Key Financial Metrics
The provided filing text does not contain specific financial data. Consequently, the following metrics are not available in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt Levels
- Liquidity Position
Note: As this is a Form 6-K referencing a press release, financial figures would typically be found in the referenced Exhibit 99.1 or the company's most recent Form 20-F, neither of which are included in the input text.
Material Changes
The filing text does not describe specific material changes, operational updates, or comparative period analysis. It solely confirms the submission of a press release dated November 14, 2023, which is deemed incorporated by reference into the company's registration statement on Form F-3.
Guidance, Outlook, and Risks
The provided text does not include management commentary, future guidance, risk factors, contingencies, or details regarding unusual items. These elements are expected to be contained within the referenced press release (Exhibit 99.1), the content of which is not present in the input.
Investor Verification Checklist
- Verify the content of the Press Release dated November 14, 2023 (Exhibit 99.1) to understand the specific material event triggering this filing.
- Review the most recent Form 20-F or quarterly reports for current financial metrics, as this Form 6-K does not provide them.
- Confirm if the referenced press release impacts the company's Form F-3 registration statement (File No. 333-252074) regarding future capital raising capabilities.
- Check for any subsequent filings that may supersede the information in this report.